BRC Therapeutics Joins FDA and EMA Regulators at Workshop Advancing the Future of Botanical Drug Development
Why now
Thesis: Botanical drug rules advance, private firm focus
Catalyst to watch: FDA guidance finalization
Main risk: Pathway remains slow and uncertain
Why it matters
Botanical drug regulatory pathway progress matters for private biotech, not listed tickers.
Details
Company Applauds FDA and EMA Leadership as Regulators Prioritize a Clear Pathway for Botanical Medicines to Reach Patients MONTEREY, Calif., Sept. 28, 2026 /PRNewswire/ -- BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics for...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-28 15:44 UTC